NCT06850051View on ClinicalTrials.gov

A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Healthy VolunteersInfluenza VaccinationRespiratory Syncytial Virus VaccinationParainfluenza VaccinationHuman Metapneumovirus Vaccination
Interventions
BIOLOGICAL

TIV-HA Vaccine formulation 1 at low dose

Suspension for injection in a vial. Route of administration: IM injection

BIOLOGICAL

TIV-HA formulation 1 at high dose

Suspension for injection in a vial. Route of administration: IM injection

BIOLOGICAL

TIV-HA formulation 2 at low dose

Suspension for injection in a vial. Route of administration: IM injection

BIOLOGICAL

TIV-HA formulation 2 at high dose

Suspension for injection in a vial. Route of administration: IM injection

BIOLOGICAL

RSV/hMPV/PIV3 formulation 2 at low dose

Suspension for injection in a vial. Route of administration: IM injection

BIOLOGICAL

RSV/hMPV/PIV3 formulation 1 at high dose

Suspension for injection in a vial. Route of administration: IM injection

BIOLOGICAL

RSV/hMPV/PIV3 formulation 2 at high dose

Suspension for injection in a vial. Route of administration: IM injection

BIOLOGICAL

RSV/hMPV/PIV3 formulation 1 at low dose

Suspension for injection in a vial. Route of administration: IM injection

BIOLOGICAL

RIV4 (Supemtek®)

Solution for injection in a prefilled syringe. Route of administration: IM injection

Trial Locations (6)

2148

Paratus Clinical, Blacktown

3124

Emeritus Research, Camberwell

4006

Paratus Clinical, Herston

4101

University of Sunshine Coast Clinical Trials, South Brisbane

4215

Griffith University, Southport

4506

University of Sunshine Coast Clinical Trials, Morayfield

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06850051 - A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. | Biotech Hunter | Biotech Hunter